Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul:96:107777.
doi: 10.1016/j.intimp.2021.107777. Epub 2021 May 11.

Insights on the mechanisms of action of ozone in the medical therapy against COVID-19

Affiliations
Review

Insights on the mechanisms of action of ozone in the medical therapy against COVID-19

Salvatore Chirumbolo et al. Int Immunopharmacol. 2021 Jul.

Abstract

An increasing amount of reports in the literature is showing that medical ozone (O3) is used, with encouraging results, in treating COVID-19 patients, optimizing pain and symptoms relief, respiratory parameters, inflammatory and coagulation markers and the overall health status, so reducing significantly how much time patients underwent hospitalization and intensive care. To date, aside from mechanisms taking into account the ability of O3 to activate a rapid oxidative stress response, by up-regulating antioxidant and scavenging enzymes, no sound hypothesis was addressed to attempt a synopsis of how O3 should act on COVID-19. The knowledge on how O3 works on inflammation and thrombosis mechanisms is of the utmost importance to make physicians endowed with new guns against SARS-CoV2 pandemic. This review tries to address this issue, so to expand the debate in the scientific community.

Keywords: Anti-inflammatory; Anti-oxidant; COVID-19; Medical therapy; Ozone therapy; Review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Cartoon showing the major pathways targeted by O3 and its ROS and RES mediators on COVID-19. 1) O3 can even enter the cell via aryl-hydrocarbon receptors (AHR) and may form ROS or RES, both able to activate the Nrf2/Keap1/ARE system, inducing an anti-oxidant response. As the activation of Nrf2 blocks the NF-κB signaling, Nrf2 activation inhibits the inflammatory signal (anti-inflammatory action). 2) The anti-oxidant response is enhanced by blocking the Keap-1 mediated degradation of Nrf2; 3) The activation of Nrf2 releases HO-1, which exerts an anti-thrombotic action and moreover inhibits p65 expression and translocation into the nucleus, so suppressing the NF-κB pathway (anti-inflammatory action); 4) the HO-1 mediated anti-thrombotic action promotes the reduction of organ damage in I/R injury models, which are protected by the HO-1 stabilized HIF-1α,. Nitric oxide (NO), elicited by the anti-thrombotic action, increases the production of HO-1, so emphasizing the beneficial effect of HO-1 on vascular endothelia, dampening thrombotic mechanisms and promoting cardiovascular protection. 5) Hypoxia induces the activation of the HIF-1α pathway, which up-regulating the expression of ACE-1 receptors and subsequently down-regulating ACE2R, inhibits SARS-CoV2 spreading in the organism. HIF-1α enhances the production of HO-1. Green circles (+) = activation, red circles (-) = inhibition. Ozone is indicated by the picture with 3 full circles.

References

    1. S.N. Manjunath, M. Sakar, M. Katapadi, R. Geetha Balakrishna, Recent case studies on the use of ozone to combat coronavirus: Problems and perspectives, Environ. Technol. Innov. Feb;21 (2021) 101313. doi: 10.1016/j.eti.2020.101313. - PMC - PubMed
    1. Izadi M., Cegolon L., Javanbakht M., Sarafzadeh A., Abolghasemi H., Alishiri G., Zhao S., Einollahi B., Kashaki M., Jonaidi-Jafari N., Asadi M., Jafari R., Fathi S., Nikoueinejad H., Ebrahimi M., Imanizadeh S., Ghazale A.H. Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review. Int. Immunopharmacol. 2021;92 - PMC - PubMed
    1. Franzini M., Valdenassi L., Ricevuti G., Chirumbolo S., Depfenhart M., Bertossi D., Tirelli U. Oxygen-ozone (O2–O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported . Int Immunopharmacol. 2020;88 - PMC - PubMed
    1. Shah M., Captain J., Vaidya V., Kulkarni A., Valsangkar K., Nair P.M.K., Ganu G. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study) Int. Immunopharmacol. 2021;91 - PMC - PubMed
    1. Hernández A., Viñals M., Pablos A., Vilás F., Papadakos P.J., Wijeysundera D.N., Bergese S.D., Vives M. Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study. Int. Immunopharmacol. 2021;90 - PMC - PubMed